{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:44:44Z","timestamp":1791960284436,"version":"4.3.4"},"publisher-location":"Boston","reference-count":54,"publisher":"Kluwer Academic Publishers","isbn-type":[{"value":"0306477572","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1007\/0-306-48382-3_102","type":"book-chapter","created":{"date-parts":[[2006,2,18]],"date-time":"2006-02-18T20:57:40Z","timestamp":1140296260000},"page":"503-509","source":"Crossref","is-referenced-by-count":10,"title":["The Use of Interferon-\u03b1 in Beh\u00e7et\u2019s Disease \u2014 Review of the Literature and Possible Mechanisms of Action"],"prefix":"10.1007","author":[{"given":"Ina","family":"K\u00f6tter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilhan","family":"G\u00dcnaydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Treusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Zierhut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Kanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"St\u00dcbiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"102_CR1","unstructured":"Saenz, A., Ausejo, M., Shea, B., et al., 2000, Pharmacotherapy for Beh\u00e7et\u2019s syndrome. Cochrane Database Syst. Rev. CD001084."},{"key":"102_CR2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S0021-5155(99)00029-5","volume":"43","author":"K. Ando","year":"1999","unstructured":"Ando, K., Fujino, Y., Hijikata, K., et al., 1999, Epidemiological features and visual prognosis of Beh\u00e7et\u2019s disease. Jpn. J. Ophthalmol. 43: 312\u2013317.","journal-title":"Jpn. J. Ophthalmol."},{"key":"102_CR3","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S0161-6420(99)90120-3","volume":"106","author":"S. Kotake","year":"1999","unstructured":"Kotake, S., Higashi, K., Yoshikawa, K., et al., 1999, Central nervous system symptoms in patients with Beh\u00e7et disease receiving cyclosporine therapy. Ophthalmology 106: 586\u2013589.","journal-title":"Ophthalmology"},{"key":"102_CR4","first-page":"258","volume":"47","author":"A. Isaacs","year":"1957","unstructured":"Isaacs, A., and Lindenmann, J., 1957, Virus interference. Proc. R. Soc. Ser. B 47: 258\u2013267.","journal-title":"Proc. R. Soc. Ser. B"},{"key":"102_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1046\/j.1365-2893.1998.00103.x","volume":"5","author":"G.R. Foster","year":"1998","unstructured":"Foster, G.R., and Finter, N.B., 1998, Are all type I human interferons equivalent? J. Viral Hepat. 5: 143\u2013152.","journal-title":"J. Viral Hepat."},{"key":"102_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/BF00407749","volume":"278","author":"D. Tsambaos","year":"1986","unstructured":"Tsambaos, D., Eichelberg, D., and Goos, M., 1986, Beh\u00e7et\u2019s syndrome: treatment with recombinant leukocyte alpha-interferon. Arch. Dermatol. Res. 278: 335\u2013336.","journal-title":"Arch. Dermatol. Res."},{"key":"102_CR7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0140-6736(99)05131-4","volume":"355","author":"H. Demiroglu","year":"2000","unstructured":"Demiroglu, H., \u00d6zcebe, O.I., Barista, I., et al., 2000, Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Beh\u00e7et\u2019s disease: a randomised trial. Lancet 355: 605\u2013609.","journal-title":"Lancet"},{"key":"102_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/archderm.138.4.467","volume":"138","author":"E. Alpsoy","year":"2002","unstructured":"Alpsoy, E., Durusoy, C., Yilmaz, E., et al., 2002, Interferon alfa-2a in the treatment of Beh\u00e7et disease: a randomized placebo-controlled and double-blind study. Arch. Dermatol. 138: 467\u2013471.","journal-title":"Arch. Dermatol."},{"key":"102_CR9","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0140-6736(00)02811-7","volume":"356","author":"R. Horton","year":"2000","unstructured":"Horton, R., 2000, Retraction: interferon alfa-2b in Beh\u00e7et\u2019s disease. Lancet 356: 1292.","journal-title":"Lancet"},{"key":"102_CR10","unstructured":"Gendron, G., Wechsler, B., Bodaghi, D., et al., 2002, Efficacy and safety of interferon alfa-2a in intractable Beh\u00e7et\u2019s disease associated uveitis. In: Programme and Abstracts, 10th International Conference on Beh\u00e7et\u2019s Disease, Berlin, Germany, p. 98."},{"key":"102_CR11","first-page":"511","volume-title":"Adamantiades-Beh\u00e7et\u2019s Disease","author":"L. Krause","year":"2002","unstructured":"Krause, L., Turnbull, J.R., Torun, et al., 2002, Interferon alfa-2a in the treatment of ocular Adamantiades-Beh\u00e7et\u2019s disease. In Adamantiades-Beh\u00e7et\u2019s Disease (Ch.C. Zouboulis, ed.), Kluwer\/Plenum, London, pp. 511\u2013519."},{"key":"102_CR12","first-page":"521","volume-title":"Adamantiades-Beh\u00e7et\u2019 s Disease","author":"I. K\u00f6tter","year":"2002","unstructured":"K\u00f6tter, I., Zierhut, M., Eckstein, A., et al., 2002, Human recombinant interferon-\u03b12a (rhIFN\u03b12a) for the treatment of Beh\u00e7et\u2019s disease with sight-threatening retinal vasculitis. In Adamantiades-Beh\u00e7et\u2019 s Disease (Ch.C. Zouboulis, ed.), Kluwer\/Plenum, London, pp. 521\u2013523."},{"issue":"suppl. 1","key":"102_CR13","first-page":"212","volume":"61","author":"I. K\u00f6tter","year":"2002","unstructured":"K\u00f6tter, I., Zierhut, M., Eckstein, A., et al., 2002, Human recombinant interferon-alpha2a in the treatment of Beh\u00e7et\u2019s disease with sight threatening retinal vasculitis. Ann. Rheum. Dis. 61 (suppl. 1): 212.","journal-title":"Ann. Rheum. Dis."},{"key":"102_CR14","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1055\/s-2001-19687","volume":"218","author":"N. St\u00fcbiger","year":"2001","unstructured":"St\u00fcbiger, N., K\u00f6tter, I., Deuter, C. et al., 2001, [Beh\u00e7et\u2019s disease: uveitis-therapy with interferon alpha2a\u2014prospective clinical study in 33 patients]. Klin. Monatsbl. Augenheilkd. 218: 768\u2013773.","journal-title":"Klin. Monatsbl. Augenheilkd"},{"key":"102_CR15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00041327-200106000-00011","volume":"21","author":"J.C. Nichols","year":"2001","unstructured":"Nichols, J.C., Ince, A., Akduman, L., et al., 2001, Interferon-alpha 2a treatment of neuro-Beh\u00e7et disease. J. Neuroophthalmol. 21: 109\u2013111.","journal-title":"J. Neuroophthalmol."},{"key":"102_CR16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/ard.60.1.83","volume":"60","author":"I. K\u00f6tter","year":"2001","unstructured":"K\u00f6tter, I., Aepinus, C., Graepler, F., et al., 2001, HHV8 associated Kaposi\u2019s sarcoma during triple immunosuppressive treatment with cyclosporin A, azathioprine, and prednisolone for ocular Beh\u00e7et\u2019s disease and complete remission of both disorders with interferon alpha. Ann. Rheum. Dis. 60: 83\u201386.","journal-title":"Ann. Rheum. Dis."},{"key":"102_CR17","first-page":"43","volume":"73","author":"M. Kacunaros","year":"2001","unstructured":"Kacunaros, M., Alicanidu, O., Balacucas, D., et al., 2001, [Adamantiadi-Beh\u00e7et syndrome: treatment with recombinant leukocytic interferon]. Ter. Arkh. 73: 43\u201345.","journal-title":"Ter. Arkh."},{"key":"102_CR18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1076\/ocii.8.4.293.6453","volume":"8","author":"B. Wechsler","year":"2000","unstructured":"Wechsler, B., Bodaghi, B., Huong, D.L., et al., 2000, Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Beh\u00e7et\u2019s disease. Ocul. Immunol. Inflamm. 8: 293\u2013301.","journal-title":"Ocul. Immunol. Inflamm."},{"key":"102_CR19","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/bjo.84.12.1432g","volume":"84","author":"N. Stuebiger","year":"2000","unstructured":"Stuebiger, N., Koetter, I., and Zierhut, M., 2000, Complete regression of retinal neovascularization after therapy with interferon alfa in Beh\u00e7et\u2019s disease. Br. J. Ophthalmol. 84: 1437\u20131438.","journal-title":"Br. J. Ophthalmol."},{"key":"102_CR20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000018427","volume":"201","author":"A. Boyvat","year":"2000","unstructured":"Boyvat, A., Sisman-Solak, C., and G\u00fcrler, A., 2000, Long-term effects of interferon alpha 2A treatment in Beh\u00e7et\u2019s disease. Dermatology 201: 40\u201343.","journal-title":"Dermatology"},{"key":"102_CR21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2169\/internalmedicine.39.667","volume":"39","author":"T. Aoki","year":"2000","unstructured":"Aoki, T., Tanaka, T., Akifuji, Y., et al., 2000, Beneficial effects of interferon-alpha in a case with Beh\u00e7et\u2019s disease. Intern. Med. 39: 667\u2013669.","journal-title":"Intern. Med."},{"key":"102_CR22","first-page":"448","volume-title":"Beh\u00e7et\u2019s disease","author":"V. Hamuryudan","year":"2000","unstructured":"Hamuryudan, V., \u00d6zyazgan, Y., Fresko, I., et al., 2000, Treatment of severe uveitis of Beh\u00e7et\u2019s syndrome with the combination of interferon alfa 2b and azathioprine: An open study. In Beh\u00e7et\u2019s disease (D. Bang, E.-S. Lee, and S. Lee, eds.), Design Mecca Publishing Co., Seoul, Korea, p. 448."},{"key":"102_CR23","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1001\/archderm.134.8.1010","volume":"134","author":"Ch.C. Zouboulis","year":"1998","unstructured":"Zouboulis, Ch.C., and Orfanos, C.E., 1998, Treatment of Adamantiades-Beh\u00e7et disease with systemic interferon alfa. Arch. Dermatol. 134: 1010\u20131016.","journal-title":"Arch. Dermatol."},{"key":"102_CR24","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1046\/j.1365-2141.1998.01038.x","volume":"103","author":"R. Strohal","year":"1998","unstructured":"Strohal, R., Tschachler, E., Breyer, S., et al., 1998, Reactivation of Beh\u00e7et\u2019s disease in the course of multicentric HHV8-positive Castleman\u2019s disease: long-term complete remission by a combined chemo\/radiation and interferon-alpha therapy regimen. Br. J. Haematol. 103: 788\u2013790.","journal-title":"Br. J. Haematol."},{"key":"102_CR25","first-page":"1938","volume":"25","author":"J.D. O\u2019Duffy","year":"1998","unstructured":"O\u2019Duffy, J.D., Calamia, K., Cohen, S., et al., 1998, Interferon-alpha treatment of Beh\u00e7et\u2019s disease. J Rheumatol. 25: 1938\u20131944.","journal-title":"J Rheumatol."},{"key":"102_CR26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/bjo.82.5.488","volume":"82","author":"I. K\u00f6tter","year":"1998","unstructured":"K\u00f6tter, I., Eckstein, A.K., St\u00fcbiger, N., et al., 1998, Treatment of ocular symptoms of Beh\u00e7et\u2019s disease with interferon alpha 2a: a pilot study. Br. J. Ophthalmol. 82: 488\u2013494.","journal-title":"Br. J. Ophthalmol."},{"key":"102_CR27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1046\/j.1365-2796.1998.00159.x","volume":"243","author":"S. Georgiou","year":"1998","unstructured":"Georgiou, S., Monastirli, A., Pasmatzi, E., et al., 1998, Efficacy and safety of systemic recombinant interferon-alpha in Beh\u00e7et\u2019s disease. J. Intern. Med. 243: 367\u2013372.","journal-title":"J. Intern. Med."},{"key":"102_CR28","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1600-0420.1997.tb00638.x","volume":"75","author":"P. Pivetti-Pezzi","year":"1997","unstructured":"Pivetti-Pezzi, P., Accorinti, M., Pirraglia, M.P., et al., 1997, Interferon alpha for ocular Beh\u00e7et\u2019s disease. Acta Ophthalmol. Scand. 75: 720\u2013722.","journal-title":"Acta Ophthalmol. Scand."},{"key":"102_CR29","first-page":"453","volume-title":"Beh\u00e7et\u2019s Disease","author":"G. Azizlerli","year":"1997","unstructured":"Azizlerli, G., Sarica, R., Kose, A., et al., 1997, The long-term treatment with interferon-alfa2a in Beh\u00e7et\u2019s disease, In: Beh\u00e7et\u2019s Disease (M. Hamza, ed.), Pub Adhoua, Tunis, p. 453\u2013455."},{"key":"102_CR30","first-page":"293","volume":"196","author":"J. Sanchez Roman","year":"1996","unstructured":"Sanchez Roman, J,, Pulido Aguilera, M.C., Castillo Palma, M.J., et al. 1996, [The use of interferon alfa-2r in the treatment of autoimmune uveitis (primary or associated with Beh\u00e7et\u2019s disease)]. Rev. Clin. Esp. 196: 293\u2013298.","journal-title":"Rev. Clin. Esp."},{"key":"102_CR31","first-page":"313","volume":"14","author":"I. K\u00f6tter","year":"1996","unstructured":"K\u00f6tter, I., D\u00fcrk, H., Eckstein, A., et al., 1996, Erosive arthritis and posterior uveitis in Beh\u00e7et\u2019s disease: treatment with interferon alpha and interferon gamma. Clin. Exp. Rheumatol. 14: 313\u2013315.","journal-title":"Clin. Exp. Rheumatol."},{"key":"102_CR32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000246374","volume":"192","author":"G. Azizlerli","year":"1996","unstructured":"Azizlerli, G., Sarica, R., Kose, A., et al., 1996, Interferon alfa-2a in the treatment of Beh\u00e7et\u2019s disease. Dermatology 192: 239\u2013241.","journal-title":"Dermatology"},{"key":"102_CR33","first-page":"285","volume":"9","author":"S. D\u00fcndar","year":"1996","unstructured":"D\u00fcndar, S., Demiroglu, H., \u00d6zcebe, O., et al., 1996, Alpha interferon in Beh\u00e7et\u2019s disease. Hematol. Rev. 9. 285\u2013290.","journal-title":"Hematol. Rev."},{"key":"102_CR34","first-page":"559","volume":"63","author":"Ch.C. Zouboulis","year":"1996","unstructured":"Zouboulis, Ch.C., and Orfanos, C.E., 1996, Systemic interferon-alfa in the treatment of Adamantiades-Beh\u00e7et\u2019s disease. Rev. Rhum. (Engl. Ed.) 63: 559.","journal-title":"Rev. Rhum. (Engl. Ed.)"},{"key":"102_CR35","first-page":"1098","volume":"21","author":"V. Hamuryudan","year":"1994","unstructured":"Hamuryudan, V., Moral, F., Yurdakul, S., et al., 1994, Systemic interferon alpha 2b treatment in Beh\u00e7et\u2019s syndrome. J. Rheumatol. 21: 1098\u20131100.","journal-title":"J. Rheumatol."},{"key":"102_CR36","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/S0140-6736(94)92549-6","volume":"343","author":"E.J. Feron","year":"1994","unstructured":"Feron, E.J., Rothova, A., van Hagen, P.M., et al., 1994, Interferon-alpha 2b for refractory ocular Beh\u00e7et\u2019s disease. Lancet 343: 1428.","journal-title":"Lancet"},{"key":"102_CR37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0140-6736(94)91371-4","volume":"344","author":"J.M. Durand","year":"1994","unstructured":"Durand, J.M., and Soubeyrand, J., 1994, Interferon-alpha 2b for refractory ocular Beh\u00e7et\u2019s disease. Lancet 344: 333.","journal-title":"Lancet"},{"key":"102_CR38","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0190-9622(94)70226-8","volume":"31","author":"E. Alpsoy","year":"1994","unstructured":"Alpsoy, E., Yilmaz, E., and Basaran, E., 1994, Interferon therapy for Beh\u00e7et\u2019s disease. J. Am. Acad. Dermatol. 31: 617\u2013619.","journal-title":"J. Am. Acad. Dermatol."},{"key":"102_CR39","first-page":"440","volume":"44","author":"Ch.C. Zouboulis","year":"1993","unstructured":"Zouboulis, Ch.C., Treudler, R., and Orfanos, C.E., 1993, [Adamantiades-Beh\u00e7et disease. Therapeutic administration of systemic recombinant interferon-alpha-2a]. Hautarzt 44: 440\u2013445.","journal-title":"Hautarzt"},{"key":"102_CR40","doi-asserted-by":"crossref","unstructured":"Durand, J.M., Kaplanski, G., Telle, H., et al., Beneficial effects of interferon-alpha 2b in Beh\u00e7et\u2019s disease. Arthritis Rheum. 36: 1025\u20131026.","DOI":"10.1002\/art.1780360721"},{"key":"102_CR41","first-page":"453","volume":"38","author":"R. Stadler","year":"1987","unstructured":"Stadler, R., Bratzke, B., and Orfanos, C.E., 1987, [Therapeutic use of alpha interferon in metastasizing malignant melanoma, disseminated Kaposi sarcoma and severe Beh\u00e7et disease]. Hautarzt 38: 453\u2013460.","journal-title":"Hautarzt"},{"key":"102_CR42","first-page":"97","volume":"38","author":"R. Stadler","year":"1987","unstructured":"Stadler, R., Bratzke, B., and Baumann, I., 1987, [Beh\u00e7et disease and exogenous interferon. A successful treatment study using recombinant alpha-A-IFN]. Hautarzt 38: 97\u2013100.","journal-title":"Hautarzt"},{"key":"102_CR43","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/0167-5699(96)10027-X","volume":"17","author":"F. Belardelli","year":"1996","unstructured":"Belardelli, F., and Gresser, I., 1996, The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today 17: 369\u2013372.","journal-title":"Immunol. Today"},{"key":"102_CR44","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1359-6101(01)00022-3","volume":"13","author":"F. Belardelli","year":"2002","unstructured":"Belardelli, F., Ferrantini, M., Proietti, E., et al., 2002, Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13: 119\u2013134.","journal-title":"Cytokine Growth Factor Rev."},{"key":"102_CR45","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/0145-2126(92)90047-B","volume":"16","author":"R. Metzger","year":"1992","unstructured":"Metzger, R., Heckl-\u00d6streicher, B., Nerl, C., et al., 1992, Immunological studies of gamma delta T cells in a case of large granular lymphocyte (LGL) leukemia: leukemic gamma delta+ T cells are resistant to growth stimulation in vitro but respond to interferon-alpha treatment in vivo. Leuk. Res. 16: 1087\u20131095.","journal-title":"Leuk. Res."},{"key":"102_CR46","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-2249.1992.tb06470.x","volume":"88","author":"K. Eguchi","year":"1992","unstructured":"Eguchi, K., Kawakami, A., Nakashima, M., et al., 1992, Interferon-alpha and dexamethasone inhibit adhesion of T cells to endothelial cells and synovial cells. Clin. Exp. Immunol. 88: 448\u2013454.","journal-title":"Clin. Exp. Immunol."},{"key":"102_CR47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/bio.606","volume":"16","author":"T. Koie","year":"2001","unstructured":"Koie, T., Suzuki, K., Shimoyama, T., et al., 2001, Effect of interferon-alpha on production of reactive oxygen species by human neutrophils. Luminescence 16: 39\u201343.","journal-title":"Luminescence"},{"key":"102_CR48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1006\/cyto.1999.0557","volume":"12","author":"K. Nyhlen","year":"2000","unstructured":"Nyhlen, K., Linden, M., Andersson, R., et al., 2000, Corticosteroids and interferons inhibit cytokine-induced production of IL-8 by human endothelial cells. Cytokine 12: 355\u2013360.","journal-title":"Cytokine"},{"key":"102_CR49","first-page":"495","volume":"18","author":"A. Accardo-Palumbo","year":"2000","unstructured":"Accardo-Palumbo, A., Triolo, G., Carbone, M.C., et al., 2000, Polymorphonuclear leukocyte myeloperoxidase levels in patients with Beh\u00e7et\u2019s disease. Clin. Exp. Rheumatol. 18: 495\u2013498.","journal-title":"Clin. Exp. Rheumatol."},{"key":"102_CR50","first-page":"126","volume":"71","author":"K. Hamzaoui","year":"1988","unstructured":"Hamzaoui, K., Ayed, K., Hamza, M., et al., 1988, Natural killer cells in Beh\u00e7et\u2019s disease. Clin. Exp. Immunol. 71: 126\u2013131.","journal-title":"Clin. Exp. Immunol."},{"key":"102_CR51","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000018426","volume":"201","author":"J. Katsantonis","year":"2000","unstructured":"Katsantonis, J., Adler, Y., Orfanos, C.E., et al., 2000, Adamantiades-Beh\u00e7et\u2019s disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology 201: 37\u201339.","journal-title":"Dermatology"},{"key":"102_CR52","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s004030000128","volume":"292","author":"Ch.C. Zouboulis","year":"2000","unstructured":"Zouboulis Ch.C., Katsantonis, J., Ketteler, R., et al., 2000, Adamantiades-Beh\u00e7et\u2019s disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch. Dermatol. Res. 292: 279\u2013284.","journal-title":"Arch. Dermatol. Res."},{"key":"102_CR53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/09629350220131935","volume":"11","author":"C. Evereklioglu","year":"2002","unstructured":"Evereklioglu, C., Er, H., T\u00fcrkoz, Y., et al., 2002, Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Beh\u00e7et\u2019s disease. Mediators Inflamm. 11: 87\u201393.","journal-title":"Mediators Inflamm"},{"key":"102_CR54","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1046\/j.1365-2249.1999.01069.x","volume":"118","author":"J. Freysdottir","year":"1999","unstructured":"Freysdottir, J., Lau, S., and Fortune, F., 1999, Gamma delta T cells in Beh\u00e7et\u2019s disease (BD) and recurrent aphthous stomatitis (RAS). Clin. Exp. Immunol. 118: 451\u2013457.","journal-title":"Clin. Exp. Immunol."}],"container-title":["Advances in Experimental Medicine and Biology","Adamantiades-Beh\u00e7et\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/0-306-48382-3_102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T04:30:28Z","timestamp":1619497828000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/0-306-48382-3_102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[null]]},"ISBN":["0306477572"],"references-count":54,"URL":"https:\/\/doi.org\/10.1007\/0-306-48382-3_102","relation":{},"subject":[]}}